Mazdutide
Investigational dual GLP-1 / glucagon receptor agonist for glycemic and weight endpoints.
Overview
Emerges in metabolic trial discourse; outcomes are indication- and phase-specific.
What it is
Synthetic peptide incretin / glucagon co-agonist.
Mechanism (high level)
Dual agonism at GLP-1R and GCGR with class-typical GI and heart-rate considerations in trials.
Quick facts
- Dosage
- Trial-dependent (not for self-dosing)
- Route
- Subcutaneous in studies
- Cycle
- Per protocol
- Storage
- Per sponsor label
Research indications
- T2D and obesity trial endpoints
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Off-label stacking with other incretins
Often combined with
- Cardiovascular risk monitoring when prescribed
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- GI effects, gallbladder disease history — discuss with prescriber.
Regulatory notes
- Investigational; not broadly available outside trials.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.